NIPRIDE
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
May 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
NIPRIDE by Roche is 12. Approved for acute heart failure to reduce, left ventricular end-diastolic pressure, pulmonary capillary wedge pressure and 2 more indications. First approved in 1974.
Drug data last refreshed 7h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NIPRIDE (sodium nitroprusside) is an intravenous vasodilator that produces nitric oxide to reduce vascular smooth muscle tone. It is indicated for acute heart failure management by reducing preload and afterload through peripheral arterial and venous dilation. The drug acts within 1-2 minutes and is cleared rapidly (2-minute half-life) via hemoglobin interaction.
LOE Approaching
Product is approaching loss of exclusivity with low linked job activity, indicating a mature, stable portfolio brand with minimal growth investment.
Mechanism of Action
12.1 Mechanism of Action Sodium nitroprusside interacts with oxyhemoglobin to produce methemoglobin, cyanide, and nitric oxide (NO). NO then reacts with guanylate cyclase in vascular smooth muscle to produce cGMP that reduces intracellular calcium concentrations resulting in relaxation of vascular…
Worked on NIPRIDE at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.